Itzhak Goldberg

Itzhak Goldberg is a prominent figure in the biotechnology sector, serving as the CEO and Executive Chairman of Angion Biomedica Corporation, a company he founded in 1998. His leadership has been instrumental in guiding Angion through various phases of growth and innovation, particularly in the fields of drug development and regenerative medicine.

Educational Background and Early Career

Dr. Goldberg holds a Ph.D. in Economics from the University of Chicago and has an extensive background in academia and clinical practice. Before founding Angion, he was a faculty member at Harvard Medical School and served as the Radiation Oncologist-in-Chief for the North Shore-LIJ Health System in New York. He also held a professorship at the Albert Einstein College of Medicine, where he contributed significantly to research on tyrosine kinase receptors and hepatocyte growth factors.13

Contributions to Angion

Under his leadership, Angion has received substantial non-dilutive funding from various government sources, including the NIH and DOD, which has supported its research initiatives. Dr. Goldberg's vision for Angion has focused on leveraging innovative approaches to address unmet medical needs, particularly in organ protection and regeneration.12

Current Role and Impact

As CEO, Dr. Goldberg continues to oversee the strategic direction of Angion, ensuring that it remains at the forefront of biomedicine. His dual role as Executive Chairman allows him to influence both operational and scientific strategies within the company.5 Additionally, he is recognized for his contributions to clinical oncology and his efforts in advancing cancer treatment methodologies through research and development initiatives.46

In summary, Itzhak Goldberg is a distinguished leader in biomedicine with a rich academic background and a proven track record in fostering innovation within Angion Biomedica.